When does Innate Pharma report earnings and why does it matter for IPH.PA stock?

Innate Pharma reports after market on 26 Mar 2026. The earnings call may reveal trial progress, partnership milestones, and cash runway, all of which directly affect IPH.PA stock volatility and near-term valuation.

What is Meyka AI's forecast for IPH.PA stock and how should I use it?

Meyka AI's forecast model projects a yearly price of €1.39 for IPH.PA stock, implying an 18.80% upside from €1.17. Use this as a model-based projection, not a guaranteed outcome, and combine it with fundamental analysis.

What are the main financial risks for IPH.PA stock after earnings?

Key risks include negative EPS (currently -0.55), high debt-to-equity of 5.25, and potential dilution if Innate Pharma needs to raise capital. Earnings commentary on cash and milestones will be critical.

Which clinical programs will most influence IPH.PA stock in the report?

Monalizumab (Phase III) and Lacutamab (Phase II) are the primary drivers. Positive updates or clarified timelines for these programs would be the strongest near-term catalysts for IPH.PA stock.

EU Stocks

IPH.PA Innate Pharma S.A. EURONEXT 24 Mar 2026 intraday: earnings preview ahead

ByDanny Kontos March 24, 2026March 24, 2026

IPH.PA stock is trading intraday at €1.17, up 8.94% as traders position ahead of Innate Pharma S.A.’s scheduled earnings release later this week. The biotech moves on low float and active volume of 408,020 shares versus an average of 166,477. Market focus will be on clinical development updates for Monalizumab and Lacutamab and any guidance on partnerships or cash runway. We examine valuation, running catalysts, and short-term trade setups before the 26 Mar 2026 announcement.